
Red Vine Leaf Benefits: What the AS 195 Extract Trials Show
Quick answer. Red vine leaf is the dried leaf of red-leaved grapevines (Vitis vinifera), rich in flavonols and anthocyanins. Almost every controlled human trial tested one standardized water extract, AS 195, in adults with chronic venous insufficiency (CVI), a condition of leg swelling, heaviness and pain caused by poorly working leg veins. In those trials, 360 to 720 mg a day for 6 to 12 weeks reduced lower-leg volume and some symptoms more than placebo, but in the 2011 trial in more advanced CVI the effect was small (about 20 mL), and two 12-week trials at 360 mg a day, known only from unpublished company reports, found no significant leg-volume difference. Side effects judged related to the extract were uncommon and mostly mild, such as stomach upset and skin reactions; the European Medicines Agency (EMA) does not recommend it in pregnancy, breastfeeding or for people under 18.
What red vine leaf is
Red vine leaf comes from grapevine varieties whose leaves turn red. The European Union herbal monograph calls it Vitis vinifera L., folium. In a study of 135 samples of red vine leaves from different varieties and origins, total flavonols ranged from 0.6% to 3.5%, anthocyanins from 0.2% to 1.45%, and total polyphenols from 4.6% to 18.9%. The main flavonols are quercetin glucuronide and isoquercitrin (a quercetin glucoside).
The tested extract. AS 195 is the code name of the extract in a European over-the-counter medicine. Clinical papers describe it as a red vine leaf extract containing flavonoids, mainly quercetin-3-O-glucuronide and isoquercitrin. EMA's assessment report describes the tablets in one 360 mg trial as a water extract with a drug-to-extract ratio of 4–6:1 (4 to 6 kg of leaf per kg of extract), and notes that one water extract of red vine leaf contains 4% to 7% flavonol glycosides. The trials tested the extract as a whole, not single compounds.
Forms on the market. EMA's monograph covers three kinds of preparation: the dry water extract (4–6:1); cut leaf for tea and powdered leaf; and a soft extract for creams. Raw material varies: in 2026, Italian researchers analyzing commercial red vine leaves found anthocyanins ranging from 0.49 to 5.64 mg/g between lots. In a 2016 Japanese government lab study, flavonol and stilbene levels stayed constant in red vine leaf medicines but varied in health-food products, even within one lot of the same brand.
Regulatory status. EMA's herbal committee adopted the current monograph in May 2017. It accepts the 4–6:1 dry water extract under "well-established use," a category based on published data and at least 10 years of medical use in the EU, for CVI with swollen legs, varicose veins, heaviness, pain, tiredness, itching, tension and calf cramps. Teas, powders and creams are accepted only as "traditional use," based on long use rather than trials, for leg discomfort from minor venous circulation problems, hemorrhoid itching and fragile skin capillaries. A periodic review adopted in May 2025 found no new clinical data that would call for a revision. In Japan, the extract has been approved as a nonprescription drug. In the U.S., red vine leaf is sold as a dietary supplement, and the FDA does not approve supplements for safety or effectiveness.
What human studies have tested
| Study | Who took part | Form and daily amount | Duration | What was measured | Result |
|---|---|---|---|---|---|
| Kiesewetter et al., 2000 (randomized, double-blind, placebo-controlled; Germany) | 260 adults aged 25 to 75 with mild CVI (stage I to early stage II), not using compression stockings; 257 analyzed | AS 195, 360 or 720 mg once daily, vs placebo | 12 weeks | Lower-leg volume (water displacement), calf and ankle circumference, symptoms | Leg volume vs placebo: −75.9 g (95% CI −106.1 to −45.8) with 360 mg and −99.9 g (−130.3 to −69.6) with 720 mg; placebo legs grew by 33.7 g. Calf circumference fell; symptoms improved more than placebo by week 12. EMA noted most measurements were made by two investigators. ClinicalTrials.gov lists the manufacturer as sponsor (paper's funding statement not seen) |
| Kalus et al., 2004 (randomized, double-blind, placebo-controlled crossover; Germany) | 71 adults with CVI stage I or II | AS 195, 360 mg once daily, vs placebo | Two 6-week periods, 4-week washout | Skin blood flow at the ankle (laser Doppler), skin oxygen (tcpO2), leg circumference | Skin blood flow +241.8 vs −41.0 arbitrary units; tcpO2 +1.35 vs −7.27 mmHg; ankle −0.39 vs +0.29 cm; calf −0.54 vs +0.14 cm (all p < 0.0001). ClinicalTrials.gov lists the manufacturer as sponsor (paper's funding statement not seen) |
| Schaefer & Petrini, 2004 (randomized, placebo-controlled; unpublished company report summarized by EMA) | 247 adults with CVI, CEAP class C3 (edema) or C4a (skin changes) | AS 195, 360 mg once daily, vs placebo | 12 weeks | Leg volume at day 84 (main goal), symptoms | Leg volume difference −10.42 (95% CI −33.76 to 12.92), not significant. Leg tension (day 42) and leg pain (day 84) improved more than placebo |
| Vix et al., 2007 (randomized, double-blind, placebo-controlled, multicenter; unpublished company report summarized by EMA) | Adults with CVI; number and disease stage not given in EMA's summary | 4–6:1 water extract tablets, 360 mg a day, vs placebo | 12 weeks | Leg volume at day 84, calf circumference, symptoms, global rating, quality of life | Leg volume −21.38 g vs −10.71 g, difference not significant. Calf circumference at day 42 borderline (p = 0.0596). Symptoms other than tingling favored the extract at day 42 (significance not stated). "Good or satisfactory" ratings 70.9% vs 67.7%; quality of life not significantly different |
| Rabe et al., 2011 (randomized, double-blind, placebo-controlled, multicenter; Germany) | 250 adults with CVI, CEAP C3–C4a, moderate-to-severe symptoms; 248 analyzed; 81.5% women, mean age 58 | AS 195, 720 mg a day (two 360 mg tablets), vs placebo | 12 weeks | Leg volume (main goal), symptoms on a 10-cm scale, global ratings | Leg volume −19.9 mL vs placebo (95% CI −37.5 to −2.3). At week 12, leg pain −6.6 mm vs placebo (p = 0.047), other symptoms not significant; leg tension lower at week 6 (−6.5 mm, p = 0.031). Patients rating effect good or satisfactory: 70% vs 59%, not significant. Funded by the manufacturer; two authors were its employees |
| Azhdari et al., 2020 (systematic review) | 5 trials selected from 56 studies | AS 195 | 6 to 12 weeks | Leg volume, circumference, symptoms, skin microcirculation | Improvements "in only some trials"; called for higher-quality trials |
| Psachoulia et al., 2026 (randomized, double-blind, placebo-controlled; Greece) | 58 adults with chronic venous disease, CEAP C2–C3 | A "new formulation" of a red vine leaf-containing supplement; extract and dose not given in the abstract | 8 weeks | Symptoms, leg edema, quality of life, inflammation markers | Numbness and tingling scores and a quality-of-life score (CIVIQ-20) improved more than placebo; ankle and calf circumference did not differ; IL-6 fell in the supplement group |
Open-label studies from Belgium and Russia, and one run by the manufacturer, reported smaller legs and fewer symptoms over 6 weeks to 6 months at 360 or 720 mg a day. Without a placebo group, they cannot show that the extract caused the change.
What the findings suggest
Leg swelling (volume). Two published placebo-controlled trials found less leg volume with AS 195. The 2000 trial, in mild CVI, reported reductions of about 76 to 100 g of displaced water (roughly the same in milliliters) over 12 weeks. The 2011 trial, in patients with visible edema or skin changes (CEAP C3–C4a), found about 20 mL at 720 mg, a standardized effect size of 0.28 that its authors called clinically relevant. At 360 mg, two 12-week company trials, one in the same kind of patients, found no significant difference. Evidence strength: moderate that AS 195 reduces leg volume slightly in CVI, with the size of the effect uncertain and smaller in more advanced disease.
Symptoms. Heaviness, tension, tingling and pain improved more than placebo in the 2000 trial by week 12. In the 2011 trial, leg pain was lower at week 12 (by 6.6 mm on a 100 mm scale) and leg tension at week 6, but other symptoms and patients' overall ratings did not differ significantly from placebo. Evidence strength: low to moderate, with inconsistent results across trials and symptoms.
Skin microcirculation. One crossover trial in 71 patients found higher skin blood flow and oxygen at the ankle after 6 weeks of 360 mg. These are measures of blood flow in the skin, not outcomes patients feel. No second trial has repeated it. Evidence strength: low.
Dose. In the only placebo-controlled trial that compared doses, 720 mg gave a "slightly greater and more sustained improvement" than 360 mg, with similar tolerability. The EU monograph lists 360 to 720 mg once daily for the extract, for 12 weeks, noting that 2 to 3 weeks may pass before benefit. These are amounts studied for one extract, not a recommendation for any product.
Other uses. Claims about blood sugar, cholesterol, blood pressure, cancer, digestion, skin aging and immunity rest on lab and animal studies. Proposed vein mechanisms come from cell studies, such as higher nitric oxide production and less oxidative stress in cultured cells exposed to AS 195. We found no human trial of red vine leaf for these other uses.
Where the evidence is limited or conflicting
- One extract, one sponsor. Each controlled AS 195 trial we found names its manufacturer as sponsor (paper or registry) or is a report it provided to EMA. The only independent synthesis we found, a 2020 systematic review, reported benefits "in only some trials." We found no placebo-controlled trial of the extract by an independent group.
- Null trials outside the journals. The two 360 mg trials without a significant leg-volume effect exist as unpublished company reports, summarized in EMA's assessment report. ClinicalTrials.gov lists two 12-week, 360 mg trials by the manufacturer (2004, 245 enrolled; 2006, 202 enrolled) with no posted results.
- Shrinking effect. The leg-volume effect in the 2000 trial was about four to five times larger than in the 2011 trial. The trials differed in disease stage, dose and number of measuring centers, so the cause of the gap is unclear.
- Outside major pooled analyses. The 2020 Cochrane review of phlebotonics (vein-acting drugs) did not list red vine leaf among its agents. A 2025 review called its edema results "not consistent across all studies," and an Italian expert panel reached no consensus on using it alone.
- No absorption data. EMA states that human pharmacokinetic data are not available. Without them, there is no way to estimate how a different extract or dose compares with AS 195.
- Combinations untested. Products often pair red vine leaf with horse chestnut. A PubMed search found no published trial of that pair alone. Our horse chestnut review covers that herb's own trials.
Safety
In trials. In the 2011 trial, adverse events occurred in 23.8% of people on AS 195 and 35% on placebo; events judged related to treatment were 4% vs 3% and, across both groups, included flatulence, dizziness and hives. Serious events were equal (4 per group), and none was judged drug-related. In a 6-week open safety study of 65 patients at 360 mg, 6 had events possibly linked to the extract, 4 of them digestive. A 2026 network meta-analysis of venous disease drugs reported fewer adverse events with red vine leaf extract than with control (RR 0.62).
EU monograph. For the dry extract, EMA lists skin hypersensitivity reactions (itching, redness, hives) of unknown frequency; for traditional preparations it adds nausea, digestive complaints and headache. Allergy to the herb is the only contraindication. EMA advises seeing a doctor if there is skin inflammation, a vein clot or inflamed vein (thrombophlebitis), skin ulcers, sudden swelling of one or both legs, or heart or kidney failure, and if symptoms do not improve within about 2 weeks, because leg swelling can have other causes.
After marketing. EMA's 2025 review described reported reactions (itching, rash, nausea, stomach discomfort) as mostly not serious, with very rare serious events; some people over 80 with heart problems had more serious problems. A South Korean insurance-claims study recorded more adverse events with the leaf dry extract than with other vein drugs; it had no data on their severity.
Pregnancy, breastfeeding and children. EMA states that safety in pregnancy and breastfeeding "has not been established" and does not recommend use, and it does not recommend use under 18 because data are lacking.
Medicines. EMA lists interactions as "not known," and its assessment notes that interaction studies are lacking, so the absence of reports is not proof of safety. In EMA's 2025 review, some reports involved people also taking other medicines, including the blood thinner clopidogrel, and the review did not say which product caused each reaction. We found no human study testing red vine leaf with blood thinners. If you take blood thinners or other regular medicines, ask your doctor or pharmacist first. We found no official upper intake limit.
What research does not establish
- That red vine leaf in general, rather than the AS 195 extract, reduces leg swelling or symptoms.
- That 360 mg a day of the extract reduces leg volume in people with edema or skin changes (CEAP C3–C4a).
- That red vine leaf lowers blood pressure, blood sugar or cholesterol, prevents clots or cancer, or helps digestion or skin aging in people.
- That red vine leaf combined with horse chestnut works better than either alone.
- That red vine leaf is safe in pregnancy, breastfeeding, childhood or with blood thinners.
How we reviewed the evidence
On November 9, 2026, we searched PubMed for red vine leaf, AS 195 and its trade name in titles and abstracts (90 records, 84 titles screened) and for red vine leaf with venous outcomes (27 records). Targeted searches covered combinations with horse chestnut and butcher's broom, human pharmacokinetics, the Cochrane phlebotonics review and retraction status; none of the cited papers is retracted. We searched ClinicalTrials.gov (11 records for vine leaf in venous disease) and read EMA's monograph, its 2018 assessment report, the reference list and the 2025 review addendum, plus FDA's supplement page. We read full texts where available and abstracts otherwise; several older trials were available only as abstracts or through EMA's summaries. We included controlled human trials and reviews of red vine leaf, described open studies briefly, and used lab work only for mechanism. Vinatura did not run any trials.
Vinatura Research Perspective
We asked four questions: which extract and drug-to-extract ratio, what daily dose, which stage of venous disease, and whether the main outcome was met. Sorted that way, "red vine leaf benefits" narrows to one extract, AS 195, tested at 360 or 720 mg a day for up to 12 weeks, in trials sponsored by its manufacturer. Within that record, results depend on dose and disease stage. In milder CVI, both doses reduced leg volume in the 2000 trial. In people with visible edema or skin changes, 720 mg reduced leg volume by about 20 mL and eased pain, while two 360 mg trials, one in the same kind of patients, found no significant leg-volume difference. These trials are easy to overlook: we found them only in EMA's assessment, the registry lists two such trials without results, and the 2011 paper's reference list includes only the two earlier published trials, both positive.
The second gap is between trials and products. Trial results belong to a defined extract at a defined dose, and independent analyses found that commercial leaf material and health-food products varied widely.
Our assessment: moderate evidence that the AS 195 extract slightly reduces leg volume in adults with CVI, with the size of the effect uncertain; low to moderate, inconsistent evidence for symptoms; low evidence for skin microcirculation; no human evidence for other claimed benefits; and a reassuring but short-term safety record. Publication of the two 360 mg trials, an independent placebo-controlled trial of a defined extract with stated flavonol content and patient-reported outcomes, a human absorption study, and a trial of the horse chestnut combination would change this assessment.
Where this ingredient appears in Vinatura products
Red Vine Leaf extract Horse Chestnut 1300mg lists 1,100 mg of red vine leaf (Vitis vinifera) and 200 mg of horse chestnut per serving, with directions of 2 capsules a day. The page states that the leaves are harvested after the grapes, dried and extracted with purified water. The page does not specify whether this is the extract used in the trials. The studies above did not test this product.
Frequently asked questions
Is red vine leaf the same as grape seed extract? No. They come from different parts of the grapevine and contain different compounds. The venous trials described here used a leaf extract.
How much did trials use? Controlled trials gave 360 or 720 mg a day of the AS 195 extract, once daily, for 6 to 12 weeks. These are study amounts for one extract, not recommendations. Follow your product label and ask a healthcare professional.
Can red vine leaf replace compression stockings? No randomized trial has compared them directly, and the 2000 trial excluded people using stockings. Swollen or painful legs should be checked by a doctor, especially if swelling is sudden or in one leg only.
References
- Kiesewetter H, et al. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II): a randomized, double-blind, placebo-controlled trial. Arzneimittelforschung. 2000;50(2):109-117. doi:10.1055/s-0031-1300174
- Kalus U, et al. Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195: a randomised, double-blind, placebo-controlled, crossover study. Drugs R D. 2004;5(2):63-71. doi:10.2165/00126839-200405020-00001
- Rabe E, et al. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency: results of a double-blind placebo-controlled study. Eur J Vasc Endovasc Surg. 2011;41(4):540-547. doi:10.1016/j.ejvs.2010.12.003
- Azhdari M, et al. Red vine leaf extract (AS 195) can improve some signs and symptoms of chronic venous insufficiency, a systematic review. Phytother Res. 2020;34(10):2577-2585. doi:10.1002/ptr.6705
- Psachoulia F, et al. Vitis vinifera leaf extract improves quality-of-life and significantly decreases IL-6 levels in patients with chronic venous disease: a prospective, randomized, double-blind, placebo-controlled study. Int Angiol. 2026. doi:10.23736/S0392-9590.26.05549-5
- Schaefer E, et al. Oedema protective properties of the red vine leaf extract AS 195 (Folia vitis viniferae) in the treatment of chronic venous insufficiency: a 6-week observational clinical trial. Arzneimittelforschung. 2003;53(4):243-246. doi:10.1055/s-0031-1297103
- Monsieur R, Van Snick G. Efficacy of the red vine leaf extract AS 195 in chronic venous insufficiency [in French]. Praxis (Bern 1994). 2006;95(6):187-190. doi:10.1024/0369-8394.95.6.187
- Tsukanov IuT, Tsukanov AIu. Experience with six-month administration of red vine leaf extract in hormone-induced phlebopathy [in Russian]. Angiol Sosud Khir. 2014;20(3):102-107. PubMed 25267230
- Martinez-Zapata MJ, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020;11(11):CD003229. doi:10.1002/14651858.CD003229.pub4
- Gloviczki ML, et al. The role of venoactive compounds in the treatment of chronic venous disease. J Vasc Surg Venous Lymphat Disord. 2025;13(5):102258. doi:10.1016/j.jvsv.2025.102258
- Buso G, et al. Delphi consensus on the role of venoactive nutraceuticals in the management of chronic venous disease: a position statement of the Italian Society of Angiology and Vascular Medicine (SIAPAV). Nutrients. 2025;17(24):3830. doi:10.3390/nu17243830
- Nguyen AN, et al. Pharmacological interventions to treat chronic venous disease: a network meta-analysis. Phlebology. 2026. doi:10.1177/02683555261474557
- Kim H, et al. A nationwide study of compliance of venoactive drugs in chronic venous disease patients. Ann Surg Treat Res. 2023;104(5):288-295. doi:10.4174/astr.2023.104.5.288
- Schneider E, von der Heydt H, Esperester A. Evaluation of polyphenol composition in red leaves from different varieties of Vitis vinifera. Planta Med. 2008;74(5):565-572. doi:10.1055/s-2008-1034370
- Carini C, et al. Exploring the phytochemical profile of red vine (Vitis vinifera L.) leaves: compositional assessment of commercial samples. Food Chem. 2026;529:151127. doi:10.1016/j.foodchem.2026.151127
- Masada S, et al. Qualitative and quantitative evaluation of drug and health food products containing red vine leaf extracts on the Japanese market. Chem Pharm Bull (Tokyo). 2016;64(9):1275-1280. doi:10.1248/cpb.c16-00164
- Hoshino T, et al. European ethnopharmaceuticals for self-medication in Japan: review experience of Vitis vinifera L., folium extract and Vitex agnus-castus L., fructus extract as OTC drugs. Medicines (Basel). 2018;5(1):3. doi:10.3390/medicines5010003
- Grau M, et al. The red-vine-leaf extract AS195 increases nitric oxide synthase-dependent nitric oxide generation and decreases oxidative stress in endothelial and red blood cells. Pharmacol Res Perspect. 2016;4(1):e00213. doi:10.1002/prp2.213
- Nees S, et al. Protective effects of flavonoids contained in the red vine leaf on venular endothelium against the attack of activated blood components in vitro. Arzneimittelforschung. 2003;53(5):330-341. doi:10.1055/s-0031-1297117
- European Medicines Agency, Committee on Herbal Medicinal Products. European Union herbal monograph on Vitis vinifera L., folium, Revision 1 (EMA/HMPC/464684/2016). Adopted May 30, 2017. ema.europa.eu
- European Medicines Agency, Committee on Herbal Medicinal Products. Assessment report on Vitis vinifera L., folium, Revision 1 (EMA/HMPC/464682/2016). Published January 5, 2018. ema.europa.eu
- European Medicines Agency, Committee on Herbal Medicinal Products. List of references supporting the assessment of Vitis vinifera L., folium, Revision 1. ema.europa.eu
- European Medicines Agency, Committee on Herbal Medicinal Products. Addendum to assessment report on Vitis vinifera L., folium, Revision 1 (EMA/HMPC/432223/2024). Adopted May 7, 2025. ema.europa.eu
- European Medicines Agency. Vitis viniferae folium: herbal medicinal product overview page. Accessed November 9, 2026. ema.europa.eu
- ClinicalTrials.gov. NCT02191280, NCT02191163, NCT02191254, NCT00292435 and NCT00855179 (red vine leaf extract trials sponsored by the manufacturer). Accessed November 9, 2026. clinicaltrials.gov
- U.S. Food and Drug Administration. FDA 101: Dietary Supplements. Content current as of June 2, 2022. fda.gov
Editorial note: This article reviews published research for educational purposes. It does not establish the effects or safety of any specific supplement, including Vinatura products, and is not medical advice. Written by Vinatura Editorial Team. Last reviewed November 2026.
Author
Product Disclaimer
Including an ingredient or study does not evaluate, endorse, or recommend any Vinatura product or any third-party product. Some ingredients discussed may not be used in any Vinatura product.
The content of the articles has not been evaluated by the Food and Drug Administration (FDA) and is not intended to promote or endorse any specific product. Any products sold on this website are not intended to diagnose, treat, cure, or prevent any disease.
Opinions and Endorsements
Any claims, statements, or opinions expressed in the articles are those of the author(s) and do not necessarily reflect the views or opinions of the manufacturers of the dietary supplement products. The products sold on this website are separate from the content of the articles and are not directly endorsed or associated with the information presented here.
Liability Disclaimer
The author(s) of the articles, website, and manufacturers of the dietary supplement products do not assume any liability for any potential consequences arising from the use of the information provided in the articles. Ingredient effects, dosages, and safety vary by individual, formulation, and context; some ingredients interact with medications or may be unsuitable during pregnancy or lactation. It is recommended that individuals consult with a qualified healthcare professional before making any dietary or lifestyle changes, including the use of dietary supplements.
Product Usage
Please refer to the product labels and packaging for specific usage instructions and guidelines for the dietary supplement products sold on this website.
Customer Support
For any concerns or questions regarding the dietary supplement products, please contact our customer support team, who will be more than happy to assist you.


Leave a Comment
Be the first to comment.
What do you think?